MD Desk

    Indian Medicines Pharmaceutical Corporation Ltd. (IMPCL), a CPSE under the administrative Control of Ministry of AYUSH, Govt. of India is engaged in Manufacturing and Marketing of Ayurvedic and Unani Medicines. IMPCL is profit making organization since its inception.

IMPCL creates History. The story behind IMPCL’s creating history is that by recording the highest ever Turnover and Highest ever Profit for the year 2020-21. The turnover being Rs. 164 Crore and profit before tax at Rs. 15.69 Crore. Despite the continued COVID impact, IMPCL ended FY 2020-21 with 11.76% growth in Revenue from Operations.

   Though it has been a difficult year for all business the year saw IMPCL manufacturing 656 Classical Ayurvedic, 332 Unani and 71 Proprietary Ayurvedic Medicines for the various diseases spectrum. The current Product Range/ Product Mix cover entire (almost) EDL published by Ministry of AYUSH, Govt. of India.

   IMPCL has also contributed significantly towards R&D activities for the Nation building and developed 25 New Proprietary Ayurvedic Medicines and started to develop more Proprietary as well as additional classical Ayurvedic / Unani medicines.

    IMPCL presence in the Domestic Market is established for the quality standard of Ayurvedic and Unani formulations/medicines for the general public and particularly Govt. institution(s). To produce genuine, efficacious and authentic medicines by using the quality materials in compliance of mix of the ancient traditions and with latest upgraded advance tool/ technology for manufacturing.

    Recently, IMPCL has been conferred with WHO-GMP/CoPP certification by DCG(I) for 18 Ayuevedic Products. This significant certification entitles the company to export its production worldwide. IMPCL is intending to target export to some of its neighbouring countries.

    As for the Growth strategy, IMPCL is contemplating foraying into the field of veterinary Medicines and is also exploring the area of production of Homeopathy Medicines. Both these areas are complementary to our existing business and no large infrastructure or major expenditure is contemplated in both the ventures. Our existing set up could supplement both the expansion.

    With our strong commitment and unmatched product portfolio, we have been effectively managing our business, regardless of the operating environment and relentlessly working towards higher Goals set for ourselves.

                With Kind Regards,

(Dr. Mukesh Kumar)

Managing Director

Last Updated on : 07/05/2021